On June 8, 2020, the U.S. District Court for the Northern District of Illinois granted defendants’ motion to dismiss an antitrust case challenging behavior arising out of a massive collection of patents known as a “patent thicket.” In re Humira (Adalimumab) Antitrust Litigation, 2020 WL 3051309 (N.D. Ill. June 8, 2020). The court dismissed claims that such conduct constituted monopolizing sham behavior, included illegal settlements, and caused anticompetitive harm. Background Humira is an “anti-inflammatory biologic,” which is “a drug derived from living organisms that helps slow down overactive immune systems.” Id. at *2. Originally developed to treat rheumatoid arthritis, Humira “is now used to treat a variety of auto-immune disorders ranging from Crohn’s disease to plaque psoriasis.” Id.
Share on
|
|
The US District Court for the Northern District of Illinois dismisses antitrust case challenging patent thicket (Humira)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
